aTYR PHARMA INC Accumulated Other Comprehensive Income
aTYR PHARMA INC (ATYR) had Accumulated Other Comprehensive Income of -$68.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-07
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$68.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$70.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$8.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$1.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$68.00K 10-Q · filed 2026-08-07 |
| 2026-03-31 | -$70.00K 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$8.00K 10-Q · filed 2026-08-07 |
| 2025-09-30 | -$1.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$75.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$66.00K 10-Q · filed 2025-05-07 |
| 2024-12-31 | -$40.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $36.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$168.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$158.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | -$74.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$294.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$333.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | -$248.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$433.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | -$669.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$810.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$759.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$263.00K 10-K · filed 2023-03-14 |
| 2021-09-30 | -$69.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$61.00K 10-Q · filed 2021-08-11 |
| 2021-03-31 | -$57.00K 10-Q · filed 2021-05-14 |
| 2020-12-31 | -$43.00K 10-K · filed 2022-03-15 |
| 2020-09-30 | -$42.00K 10-Q · filed 2020-11-13 |
| 2020-06-30 | -$44.00K 10-Q · filed 2020-08-13 |
| 2020-03-31 | -$53.00K 10-Q · filed 2020-05-12 |
| 2019-12-31 | -$40.00K 10-K · filed 2021-03-24 |
| 2019-09-30 | -$33.00K 10-Q · filed 2019-11-14 |
| 2019-06-30 | -$32.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | -$40.00K 10-Q · filed 2019-05-14 |
| 2018-12-31 | -$60.00K 10-K · filed 2020-03-26 |
| 2018-09-30 | -$57.00K 10-Q · filed 2018-11-14 |
| 2018-06-30 | -$85.00K 10-Q · filed 2018-08-14 |
| 2018-03-31 | -$136.00K 10-Q · filed 2018-05-15 |
| 2017-12-31 | -$120.00K 10-K · filed 2019-03-26 |
| 2017-09-30 | -$63.00K 10-Q · filed 2017-11-14 |
| 2017-06-30 | -$57.00K 10-Q · filed 2017-08-14 |
| 2017-03-31 | -$68.00K 10-Q · filed 2017-05-11 |
| 2016-12-31 | -$76.00K 10-K · filed 2018-03-20 |
| 2016-09-30 | $7.00K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $19.00K 10-Q · filed 2016-08-10 |
| 2016-03-31 | -$19.00K 10-Q · filed 2016-05-11 |
| 2015-12-31 | -$171.00K 10-K · filed 2017-03-16 |
| 2015-09-30 | -$68.00K 10-Q · filed 2015-11-10 |
| 2015-06-30 | -$106.00K 10-Q · filed 2015-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |